Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Actinium Pharmaceuticals Inc

Healthcare US ATNM

1.16USD
-0.06(4.92%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.151.25
LowHigh

52 Week Range

0.951.95
LowHigh

Fundamentals

  • Previous Close 1.22
  • Market Cap47.69M
  • Volume232149
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-36.06400M
  • Revenue TTM0.09M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 0.09M
  • Diluted EPS TTM-1.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -33.88700M -38.24300M -48.81800M -33.01700M -24.77400M
Minority interest - - - - -
Net income -33.88700M -38.24300M -48.81800M -31.93000M -24.58400M
Selling general administrative 15.21M 12.08M 13.33M 12.00M 8.08M
Selling and marketing expenses - - - - -
Gross profit 0.09M -0.81100M 0.08M 1.03M 1.14M
Reconciled depreciation 0.82M 0.81M 0.75M 0.70M 0.52M
Ebit -36.24700M -38.24300M -51.92000M -34.10400M -24.96400M
Ebitda -35.42600M -37.43200M -51.13000M -33.40500M -24.44000M
Depreciation and amortization 0.82M 0.81M 0.79M 0.70M 0.52M
Non operating income net other - - - - -
Operating income -36.24700M -42.12100M -51.92000M -34.10400M -24.96400M
Other operating expenses 36.34M 42.12M 52.00M 35.13M 26.11M
Interest expense - - - -1.08700M 0.19M
Tax provision - - - - -
Interest income 2.36M 3.88M 2.73M 1.09M 0.19M
Net interest income 2.36M 3.88M 2.73M 1.09M 0.19M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.62M -1.08700M -0.19000M
Total revenue 0.09M 0.00000M 0.08M 1.03M 1.14M
Total operating expenses 36.34M 41.31M 52.00M 35.13M 26.11M
Cost of revenue - 0.81M 0.79M - -
Total other income expense net 2.36M 3.88M 3.10M 1.09M 0.19M
Discontinued operations - - - - -
Net income from continuing ops -33.88700M -38.24300M -50.14100M -33.01700M -24.77400M
Net income applicable to common shares - - - -33.01700M -24.77400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 51.77M 76.90M 81.44M 114.19M 80.39M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.38M 1.60M 1.59M 2.03M 1.92M
Total liab 43.94M 44.14M 45.07M 47.71M 6.84M
Total stockholder equity 7.83M 32.76M 36.38M 66.48M 73.55M
Deferred long term liab - - - - -
Other current liab -27.75300M -0.58000M -0.54100M -24.87000M 6.53M
Common stock 0.03M 0.03M 0.03M 0.03M 0.02M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.02M
Retained earnings -409.71300M -375.82600M -337.58300M -288.76500M -255.74800M
Other liab - - - 35.00M -
Good will - - - - -
Other assets - - 0.00000M 0.30M -
Cash 48.00M 72.90M 76.68M 108.91M 77.83M
Cash and equivalents - - - - -
Total current liabilities 7.97M 8.15M 8.49M 10.63M 6.84M
Current deferred revenue 35.00M 35.00M 35.00M 35.00M -
Net debt -46.30400M -71.33100M -74.56400M -106.32900M -77.51900M
Short term debt 0.72M 0.58M 1.08M 0.50M 0.31M
Short long term debt - - - - -
Short long term debt total 1.69M 1.57M 2.11M 2.58M 0.31M
Other stockholder equity 417.54M 408.55M 373.93M 355.22M 329.27M
Property plant equipment - - - 2.95M 0.64M
Total current assets 49.38M 74.51M 78.26M 110.94M 79.75M
Long term investments - - - - -
Net tangible assets - - - 66.48M 73.55M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable - 7.57M 7.95M 10.13M 5.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.02000M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -255.74800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.34M 0.32M 0.31M 0.30M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 2.39M 2.39M 3.18M 3.25M 0.64M
Capital lease obligations 1.69M 1.57M 2.11M 2.58M 0.31M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01100M -0.16900M -0.36600M -0.13300M
Change to liabilities - - - 38.60M 1.20M
Total cashflows from investing activities -0.10400M -0.01100M -0.15300M -0.36600M -0.13300M
Net borrowings -0.01000M -0.00900M -0.00400M -0.04900M -0.08500M
Total cash from financing activities -0.21700M 29.32M 14.87M 23.11M 35.22M
Change to operating activities - - - -0.43000M 0.49M
Net income -33.88700M -38.24300M -48.81800M -33.01700M -24.77400M
Change in cash -24.89500M -3.76200M -32.62900M 31.39M 14.22M
Begin period cash flow 73.23M 76.99M 109.31M 78.22M 64.00M
End period cash flow 48.33M 73.23M 76.68M 109.61M 78.22M
Total cash from operating activities -24.58000M -33.07200M -47.33500M 8.64M -20.86600M
Issuance of capital stock 0.00000M 29.25M 18.31M 23.16M 35.30M
Depreciation 0.82M 0.81M 0.79M 0.70M 0.52M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - 35.31M
Other cashflows from financing activities -0.20700M 0.07M 0.52M -0.36600M 0.00600M
Change to netincome - - - 2.79M 1.69M
Capital expenditures 0.10M 0.01M 0.15M 0.37M 0.13M
Change receivables - - - - -
Cash flows other operating - - - - -0.50300M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 14.22M
Change in working capital -0.70400M -0.93200M -3.14900M 38.17M 1.69M
Stock based compensation 9.19M 5.29M 3.84M 2.79M 1.69M
Other non cash items -0.70400M -0.93200M 3.84M - -11.06100M
Free cash flow -24.68400M -33.08300M -47.48800M 8.28M -20.99900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATNM
Actinium Pharmaceuticals Inc		 -0.06 4.92% 1.16 - 6.84 529.89 5.77 5.26 -3.6241
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Actinium Pharmaceuticals Inc

100 Park Avenue, New York, NY, United States, 10017

Key Executives

Name Title Year Born
Mr. Sandesh C. Seth M.B.A., M.S., MBA Chairman & CEO 1964
Mr. Steven O'Loughlin BS CFO & Corp. Sec. 1986
Dr. Paul Diamond Esq., Ph.D. VP of Patent & Legal Counsel NA
Dr. David Gould Sr. VP of Corp. Devel. & Corp. Affairs NA
Dr. Bernie Cunningham P.M.P., Ph.D. Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management NA
Dr. Qing Liang VP & Head of Radiation Sciences NA
Dr. Robert N. Daly M.S., Ph.D. VP & Head of Clinical Operations NA
Dr. Mamata Gokhale VP & Global Head of Regulatory Affairs NA
Dr. Avinash Desai M.D. Chief Medical Officer NA
Dr. Arun Swaminathan Ph.D. Chief Bus. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.